

ADVANCE PRECISION THERAPIES
WITH SCREENING-READY
NOVEL TARGET PACKAGES

# THE EXCELLENT-DATA APPROACH TO **NOVEL TARGET ID**

Indivumed Therapeutics is a biotech company focused on precision oncology. We collaborate with pharmaceutical partners, providing novel screening-ready target packages for the development of innovative cancer therapeutics. We envision a world where precision therapy offers a cure for every cancer patient.

#### A CLINICAL STANDARD TO ESTABLISH THE BASICS


Through our global clinical network, we have direct access to high-quality biospecimens and data that are crucial to making all relevant details of a cancer disease transparent. Special procedures, in particular keeping cold ischemia times to under ten minutes, ensure pre-analytically controlled specimens with a very high sample integrity. This preserves the expression of otherwise undetectable therapeutic targets. Samples are paired with 300 different clinical data points and up to ten years of follow-up data. They cover a wide variety of biological backgrounds and regional variances from all over the world.

#### UNIQUE DATA AND SAMPLES TO WORK WITH

The excellent quality of our samples enables an in-depth multi-omics approach for matched tumor and normal tissue, where we extract proteomics, phosphoproteomics, transcriptomics, genomics, and miRNA data. Following this approach over decades of collaboration, we can now draw on a unique database that reflects the molecular reality of cancer at an unparalleled level. This is the key to both advanced data analytics and end-to-end comparability across the drug development pipeline.

## **BOOSTING THE PHARMACEUTICAL INDUSTRY'S R&D PIPELINES**

To maximize the value of our data for pharmaceutical development, we have established a holistic target identification process. Each step in this process is designed to increase the probability of successful therapeutic development further down the pipeline and the chances of a novel drug reaching the market.



#### <u>∷n</u>Ravel®

#### TARGET DISCOVERY - UNRAVELLING TRILLIONS OF DATA POINTS





Once we have identified a target using nRavel®, we validate it in proprietary 2D and 3D cellular models based on immortalized cells or primary cells derived from the original patient cohort used in discovery. These models provide a very accurate recapitulation of the patient's physiological processes while representing the characteristic features of the disease.



# **TARGET PACKAGE**

### TARGET REFINEMENT - PREPARING THE PACKAGE FOR R&D PARTNERSHIPS

Our IP-protected packages consist of screening-ready targets that are set up for reproducibility within our partners' R&D pipelines. The protein type and biochemical characteristics, cellular location and biological function are biochemically characterized. Proof-of-concept drug screening assays are established for cell-free and cell-based compound screening.



#### **INDIVUMED THERAPEUTICS**

Indivumed GmbH Falkenried 88, Bldg. D 20251 Hamburg, Germany

Tel.: +49-40-4133-830
Fax: +49-40-4133-8314
Email: info@indivumed.com
www.indivumed-therapeutics.com